Pharmaceutical company Amarin Corp. (Mystic, CN) will present data from its MARINE trial, a Phase III study investigating omega-3 drug AMR101 as a treatment for very high triglycerides.
Pharmaceutical company Amarin Corp. (Mystic, CN) will present data from its MARINE trial, a Phase III study investigating omega-3 drug AMR101 as a treatment for very high triglycerides. The presentation will take place at the National Lipid Association’s 2011 annual scientific sessions in New York City on May 19-22.
The company says that, as previously reported, the MARINE trial met its primary endpoint of percent change in triglyceride levels from baseline to week 12, for both the 2- and 4-g dose groups. It also exhibited no statistically significant increase in low-density lipoprotein cholesterol and a safety profile “similar to placebo.” AMR101 is described as a pure eicosapentaenoic acid (EPA) omega-3 fatty acid.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.